Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms, including bispecific, protein engineering and antibody screening technologies. Stressing its novel immunocology candidates, Alphamab Oncology is focused on developing multi-functional cancer biologics, aiming at next-gen or best-in-class medicines that address global needs. The company has four candidates in clinical trials in the US, China, Japan and Australia.
Source: China Biotoday
